Research
Hormonal
Genetic variants in the leptin-melanocortin pathway (e.g., MC4R, PPARG) and adipokine genes (e.g., ADIPOQ) significantly influence the risk of developing obesity-associated comorbidities like type 2 diabetes and coronary heart disease, independent of total body weight.
If you have a family history of obesity or metabolic issues, get tested for genetic risk factors. This knowledge allows for earlier and more targeted monitoring of blood sugar and heart health, even if your weight is stable.
GoodSupportsHIGH confidence
Variation within the adiponectin gene is reported to modulate plasma levels of adiponectin and also to predict risk for diabesity and associated coronary heart diseases.
Why this rating
The paper cites multiple studies with statistically significant P-values for various gene associations, though it notes the complexity of polygenic effects.
Source
Genetics of obesity and the prediction of risk for health
Andrew J. Walley et al. · Human Molecular Genetics · 2006
DOI 10.1093/hmg/ddl215
narrative_reviewCited 202×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →